COTA and Aetion partner to expand access to real-world data for oncology research
This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types.
COTA-Powered Research will be Presented at the Annual Congress of the European Hematology Association
The fruits of COTA’s expanded research and consulting services — Real-World Insights and Real-World Support — will be on display at the annual Congress of the European Hematology Association (EHA) being held in Frankfurt and online June 8 – 11.
On the Ground at ISPOR 2023
Healthcare stakeholders gathered in Boston for ISPOR 2023 – the annual meeting to advance the science and practice of health economics and outcomes research (HEOR) around the world. Read insights and takeaways from the COTA team.
COTA, Inc. Expands Oncology Real-World Data Research & Consulting Services to Accelerate Safe, Effective Drug Development
COTA’s expanded services will provide even more support to organizations conducting research, like Bristol Myers Squibb, the US Food and Drug Administration, and Miami Cancer Institute. From protocol advisory and development to analytic and algorithmic support and publications, COTA’s expert guidance is a valuable asset for those looking to make advances in oncology research.
Sandy Leonard Joins COTA’s as Chief Commercial Officer to Lead Business Expansion Efforts
With over 20 years of pharmaceutical and real-world data experience, Sandy Leonard joins COTA as Chief Commercial Officer. Sandy will lead COTA’s business expansion efforts, focusing on life sciences’ growth strategy and prioritizing customer success and experience.
Real-world data control arm provides new look into effectiveness of lymphoma therapies
Real-world data can uncover vital efficacy info for new treatments. In the development of an external control arm for lisocabtagene maraleucel in patients with R/R large B-cell lymphoma, Bristol Myers Squibb used COTA’s RWD.
What to know about FDA draft guidance on accelerated approval of oncology drugs
Are you up to date with the latest FDA guidance on accelerated approvals for oncology therapeutics? The FDA has just released draft guidance on the use of randomized controlled trials (RCTs) versus single-arm trials for the accelerated approval of oncology therapies. We’ve broken down what you need to know.
Baptist Health Miami Cancer Institute expands partnership with COTA.
Miami Cancer Institute has recently utilized COTA’s analysis of RWE to change its testing policy for breast cancer gene mutations. With the new technology, the institute has decided to test every patient diagnosed with the condition. Not only will this help with early detection, but it will also allow for more personalized treatment plans.
NCCN: Enabling real-world cancer research with real-world data from COTA
Real-world data assets are becoming increasingly vital in cancer research. And at NCCN 2023, COTA’s data sets are recognized in 2 studies, one focusing on HR+, HER2- metastatic breast cancer, and the other analyzing early-stage non-small cell lung cancer.
In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership
The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data.
